Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jul 2021
Price :
$35
*
At a glance
- Drugs Molnupiravir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Ridgeback Biotherapeutics
- 03 Mar 2021 Results presented in a Ridgeback Biotherapeutics media release.
- 01 Mar 2021 Results assessing safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of molnupiravir in healthy subjects published in the Antimicrobial Agents and Chemotherapy.
- 14 Aug 2020 Status changed from recruiting to completed.